Italia markets closed

Dow Jones
39.908,00
+349,89(+0,88%)
Nasdaq
16.742,39
+231,21(+1,40%)
Nikkei 225
38.385,73
+29,67(+0,08%)
EUR/USD
1,0885
+0,0064(+0,59%)
Bitcoin EUR
60.541,38
+3.982,25(+7,04%)
CMC Crypto 200
1.391,05
+123,10(+9,70%)

NVCR Sep 2024 20.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

3,9000

+0,2300

(+6,27%)

In data: 03:43PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in